Alkem Laboratories gets USFDA warning letter with OAI classification for Daman facility


Alkem Laboratories Ltd. on Thursday, November 19, said the US drug regulator has issued official action indicated (OAI) to the company’s manufacturing facility in Amaliya, Daman.

The company said the US Food and Drug Administration (USFDA) inspected the facility from April 20, 2026 to May 1, 2026 and issued the warning letter on November 18, 2026.

Alkem said the warning letter pertains to observations made by the USFDA during its inspection of the unit and requires the company to implement appropriate corrective and preventive actions to address the observations and prevent recurrence.

Alkem Labs said it will respond to the USFDA within the stipulated timeline. It added that it continues to manufacture and supply approved products from the facility to the US market.

The company added that there is no material impact on its current operation, financial or other activities of the company.

Alkem Laboratories reported its second quarter results earlier this month.

Its net profit declined 11.7% to ₹675.3 crore from ₹765 crore in the second quarter last year. Its revenue increased 13.8% to ₹4,552 crore from ₹4,001 crore last year.

The company’s earnings before interest, taxes, depreciation and amortization (EBITDA) increased 11.3% to ₹1,025 crore from ₹921 crore last year. Its EBITDA margin contracted by 50 basis points to 22.5% from 23% in the year-ago period.

Shares of Alkem Laboratories are trading 1.7% lower on Thursday at ₹5,133. The stock is down 6% so far this year.

Also Read: NLC India Renewables files draft IPO papers; plans ₹3,300 crore fresh issue

Home/Market News/

Alkem Laboratories gets USFDA warning letter with OAI classification for Daman facility



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *